PB2171: THE NOVEL CSN5/JAB1 INHIBITOR CSN5I-3 SUPPRESSES CELL GROWTH AND UPREGULATES GENE EXPRESSION OF TYPE-I INTERFERONS (IFN) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)

por Xagoraris, I., Kokaraki, G., Stathopoulou, K., Claret, F. X., Drakos, E., Rassidakis, G. Z.
Publicado 2022

P1304: THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)

por Xagoraris, I., Kokaraki, G., Stathopoulou, K., Xyderou, P., Kurzay, A., Herold, N., Lundqvist, A., Rassidakis, G. Z.
Publicado 2022

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21...

por Drakos, E, Singh, R R, Rassidakis, G Z, Schlette, E, Li, J, Claret, F X, Ford, R J, Vega, F, Medeiros, L J
Publicado 2011

Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.

por Gorgoulis, V. G., Zacharatos, P. V., Manolis, E., Ikonomopoulos, J. A., Damalas, A., Lamprinopoulos, C., Rassidakis, G. Z., Zoumpourlis, V., Kotsinas, A., Rassidakis, A. N., Halazonetis, T. D., Kittas, C.
Publicado 1998